Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Researchers hope to determine the organ (liver and/or kidney) responsible for the increase in
endogenous glucose production (EGP) following the induction of glucosuria (when glucose is
excreted in detectable amounts in the urine) with an SGLT2 inhibitor, dapagliflozin.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio